Browse GAK

Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region Golgi apparatus, trans-Golgi network Cell junction, focal adhesion Note=Localizes to the perinuclear area and to the trans-Golgi network. Also seen on the plasma membrane, probably at focal adhesions.
Domain PF00069 Protein kinase domain
PF10409 C2 domain of PTEN tumour-suppressor protein
Function

Associates with cyclin G and CDK5. Seems to act as an auxilin homolog that is involved in the uncoating of clathrin-coated vesicles by Hsc70 in non-neuronal cells. Expression oscillates slightly during the cell cycle, peaking at G1.

> Gene Ontology
 
Biological Process GO:0006892 post-Golgi vesicle-mediated transport
GO:0006896 Golgi to vacuole transport
GO:0006898 receptor-mediated endocytosis
GO:0007009 plasma membrane organization
GO:0007029 endoplasmic reticulum organization
GO:0007030 Golgi organization
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016482 cytosolic transport
GO:0031345 negative regulation of cell projection organization
GO:0032984 macromolecular complex disassembly
GO:0034067 protein localization to Golgi apparatus
GO:0043241 protein complex disassembly
GO:0043624 cellular protein complex disassembly
GO:0045665 negative regulation of neuron differentiation
GO:0048193 Golgi vesicle transport
GO:0050768 negative regulation of neurogenesis
GO:0051261 protein depolymerization
GO:0051961 negative regulation of nervous system development
GO:0072318 clathrin coat disassembly
GO:0072319 vesicle uncoating
GO:0072583 clathrin-dependent endocytosis
GO:0072600 establishment of protein localization to Golgi
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090160 Golgi to lysosome transport
GO:1990778 protein localization to cell periphery
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0030332 cyclin binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-421837: Clathrin derived vesicle budding
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GAK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GAK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GAK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0230.937
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2050.919
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1890.898
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3320.331
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2610.919
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4270.899
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.140.69
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2830.849
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0750.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8650.585
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8340.717
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0650.257
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GAK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GAK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GAK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GAK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GAK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GAK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GAK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGAK
Namecyclin G associated kinase
Aliases DNAJC26; auxilin-2; DNAJ26; Cyclin-G-associated kinase
Chromosomal Location4p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GAK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.